8-K: Cocrystal Pharma Announces First Quarter 2025 Financial Results and Provides Updates on Antiviral Drug-Development Programs

Cocrystal Pharma reports its Q1 2025 financial results and provides updates on its antiviral product pipeline, highlighting progress with CDI-988 and CC-42344.

Summary

• Cocrystal Pharma reported its financial results for the first quarter of 2025.
• Research and development expenses decreased to $1.4 million from $3.0 million in the same quarter of the previous year, due to reduced personnel costs and the timing of clinical study costs.
• General and administrative expenses decreased to $1.0 million from $1.2 million year-over-year, primarily due to lower insurance costs.
• The net loss for the quarter was $2.3 million, or $0.23 per share, compared to a net loss of $4.0 million, or $0.39 per share, in the first quarter of 2024.
• The company's unrestricted cash was $6.9 million as of March 31, 2025, compared to $9.9 million at the end of 2024.
• Net cash used in operating activities was $2.9 million for the quarter, compared to $4.5 million in the same period last year.
• The company had working capital of $6.9 million and 10.2 million common shares outstanding as of March 31, 2025.
• Cocrystal is advancing its antiviral product pipeline, including CDI-988 for norovirus and CC-42344 for influenza.
• The company plans to initiate a human challenge study in the U.S. in the coming months to evaluate CDI-988 as a norovirus treatment and prophylaxis.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company reported a net loss and a decrease in cash reserves, it also showed progress in its clinical programs, reduced operating expenses, and improved net loss per share. The potential of its antiviral candidates and upcoming clinical trials contribute to the positive outlook.

Positives

• CDI-988 shows promise as a broad-spectrum antiviral against norovirus and coronaviruses.
• CC-42344 demonstrates strong in vitro activity against influenza A strains, including resistant strains.
• The company is advancing multiple clinical programs targeting significant viral threats.
• Research and development expenses decreased year-over-year.
• General and administrative expenses decreased year-over-year.
• Net loss per share improved compared to the same quarter last year.

Negatives

• The company experienced a net loss of $2.3 million for the quarter.
• Cash reserves decreased from $9.9 million at the end of 2024 to $6.9 million as of March 31, 2025.
• The CC-42344 Phase 2a human challenge study was extended due to unexpectedly low influenza infection among study participants.

Risks

• The company needs additional capital to fund operations over the next 12 months.
• Inflation, recession, interest rate increases, tariffs, and geopolitical conflicts could impact the company and its partners.
• Manufacturing and research delays may arise from raw materials and labor shortages, and supply chain disruptions.
• Clinical studies may face challenges in recruiting volunteers and proceeding as planned.
• Potential mutations in targeted viruses could lead to resistance against product candidates.
• Competitors may develop effective treatments that reduce or eliminate future market share.
• The company's ability to meet future liquidity needs is uncertain.

Future Outlook

The company plans to initiate a human challenge study in the U.S. in the coming months to evaluate CDI-988 as a norovirus treatment and prophylaxis and expects to report topline oral CDI-988 Phase 1 results from the high-dose healthy subject cohort in the second quarter of 2025.

Management Comments

• Sam Lee, Ph.D., President and co-CEO of Cocrystal, stated that CDI-988 is a potential breakthrough first-in-class treatment and prophylaxis for norovirus.
• James Martin, CFO and co-CEO of Cocrystal, stated that the company is advancing development of its assets for multibillion-dollar markets while remaining committed to a capital-efficient business model to maximize shareholder value.

Industry Context

Cocrystal Pharma is focused on developing antiviral therapeutics targeting influenza, coronaviruses, noroviruses, and hepatitis C viruses, addressing significant unmet needs in the global healthcare market. The company's structure-based drug discovery platform aims to create broad-spectrum antivirals that can overcome viral mutations and resistance.

Comparison to Industry Standards

• Cocrystal's approach of targeting highly conserved regions of viral enzymes aligns with industry efforts to develop broad-spectrum antivirals.
• The company's focus on norovirus is notable, as there are currently no effective treatments or vaccines available, representing a significant market opportunity.
• The estimated $10.6 billion annual burden of norovirus in the U.S. highlights the potential impact of a successful treatment.
• The global COVID-19 therapeutics market is estimated to exceed $16 billion annually by the end of 2031, indicating the significant commercial potential of Cocrystal's coronavirus program.
• Companies like Gilead Sciences and Roche are major players in the antiviral market, and Cocrystal's success will depend on its ability to differentiate its products and demonstrate superior efficacy and safety.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the progress of its clinical programs.
• Employees are affected by changes in personnel costs and the overall financial health of the company.
• Customers (potential patients) stand to benefit from the development of new antiviral treatments.
• Suppliers and vendors are impacted by the company's ability to fund its operations and research activities.
• Creditors are affected by the company's financial stability and ability to meet its obligations.

Next Steps

• Report topline oral CDI-988 Phase 1 results from the high-dose healthy subject cohort in the second quarter of 2025.
• Initiate a human challenge study in the U.S. in the coming months to evaluate CDI-988 as a norovirus treatment and prophylaxis.

Key Dates

Keywords

Cocrystal Pharma, antiviral, CDI-988, CC-42344, norovirus, influenza, coronavirus, clinical trials, financial results, drug development